Prathyusha Duraibabu
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Prathyusha Duraibabu
Earlier roles on record: CFO at Sangamo Therapeutics, Inc (SGMOQ) until February 2, 2026. Sangamo Therapeutics, Inc reported in an 8-K filed February 3, 2026 that Prathyusha Duraibabu was terminated as principal financial officer, effective February 2, 2026. Sangamo Therapeutics, Inc reported in an 8-K filed September 30, 2025 that Prathyusha Duraibabu resigned as Chief Financial Officer, effective October 1, 2025. Sangamo Therapeutics, Inc reported in an 8-K filed September 11, 2025 that Prathyusha Duraibabu resigned as Chief Financial Officer, effective October 1, 2025. The proxy statement of Sangamo Therapeutics, Inc reports total compensation of $1,186,045 for Prathyusha Duraibabu in fiscal 2024, including a base salary of $483,960. Disclosed compensation is on record for 4 fiscal years. Prathyusha Duraibabu has spoken on 10 earnings calls across 1 company, most recently for Sangamo Therapeutics, Inc on November 6, 2025.
“On February 2, 2026, the employment of Prathyusha Duraibabu, the Company's principal financial officer, terminated.”
“Prathyusha Duraibabu resigned from her position as Chief Financial Officer of Sangamo Therapeutics, Inc. (the "Company"), effective October 1, 2025 (the "Transition Date"), and is transitioning to part-time employment with the Company to continue to serve as the Company's principal financial officer.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Sangamo Therapeutics, Inc (SGMOQ)
Proxy statement
Start not stated–2021-04-02
Last confirmed by a filing; no departure on record
-
Start not stated–2026-02-02
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Sangamo Therapeutics, Inc (SGMOQ) | Chief Financial Officer | $483,960 | $1,186,045 |
| 2023 | Sangamo Therapeutics, Inc (SGMOQ) | Senior Vice President, Chief Financial Officer | $483,960 | $1,057,465 |
| 2022 | Sangamo Therapeutics, Inc (SGMOQ) | Senior Vice President, Chief Financial Officer | $436,000 | $1,293,430 |
| 2021 | Sangamo Therapeutics, Inc (SGMOQ) | Senior Vice President, Chief Financial Officer | $362,586 | $1,056,750 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.